FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:2134-2135 November 11, 2004 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: We report the development of oligospermia in a young man treated with imatinib for the hypereosinophilic syndrome. Imatinib was developed as a selective inhibitor of the BCR-ABL tyrosine kinase that is constitutively activated in chronic myeloid leukemia (CML). It also potently inhibits other normal cellular tyrosine kinases, c-abl, c-arg, and the receptors for platelet-derived growth factor (PDGF) and stem-cell factor (c-kit). Imatinib has been successfully used therapeutically against these kinases in other malignant diseases, including the hypereosinophilic syndrome.¹

The role of these tyrosine kinases in normal cellular function is still being elucidated, and their inhibition by imatinib . . . [Full Text of this Article]

This article has been cited by other articles:

• Tefferi, A., Gotlib, J., Pardanani, A. (2010). Hypereosinophilic Syndrome and Clonal Eosinophilia: Point-of-Care Diagnostic Algorithm and Treatment Update. Mayo Clin Proc. 85: 158-164 [Abstract] [Full Text]  
• Basciani, S., De Luca, G., Dolci, S., Brama, M., Arizzi, M., Mariani, S., Rosano, G., Spera, G., Gnessi, L. (2008). Platelet-Derived Growth Factor Receptor {beta}-Subtype Regulates Proliferation and Migration of Gonocytes. Endocrinology 149: 6226-6235 [Abstract] [Full Text]  
• Christopoulos, C., Dimakopoulou, V., Rotas, E. (2008). Primary Ovarian Insufficiency Associated with Imatinib Therapy. NEJM 358: 1079-1080 [Full Text]